We use cookies to give you the best possible experience on our website.

The challenges we face

Companies, especially SMEs, can face significant challenges to introduce their new and innovative products into the NHS. The complexity of public procurement, patient safety and a risk averse culture across multiple organisations can be daunting. The Innovation Nexus aims to provide a single source of resource that can help companies, particularly SMEs, understand the steps that need to be taken to support their business planning and engage with the NHS more easily, thus progressing the adoption of their innovation at pace and with fewer unanticipated obstacles.

a fully funded intensive support programme for life science SMEs working in Greater Manchester

How can the Innovation Nexus help me?

Speak directly to a GM AHSN advisor with NHS expertise

Help with navigating NHS procurement

Information about funding and investment

Help with setting up a trial of your innovation

Information on science parks and office locations

Connect you with relevant organisations

 

Free industry support from NHS experts

If you are a business with an innovative product or service that you believe has the potential to benefit the healthcare market, the Innovation Nexus can give you access a network of specialist advice and support.

Subscribe to our mailing list

* indicates required

Asset Publisher Asset Publisher

Back

1,000 patient case study published for ZedScan™

Zilico Ltd has published a 1,000 patient case study for its cervical cancer diagnostic system, ZedScan™.

The patient review in to the routine use of ZedScan as an adjunct to colposcopy has revealed that the technology significantly increases the rate of detection of high grade cervical intraepithelial neoplasia (HG CIN).

Clinicians at Sheffield Teaching Hospitals NHS Foundation Trust’s colposcopy clinic are routinely using ZedScan alongside colposcopy.  They assessed the impact of ZedScan on the patient pathway over a period of 18 months for women referred with abnormal cytology.

The data revealed that from a total of 1,052 women examined, an increase of 12.4% in the detection of high grade cervical intraepithelial neoplasia (HG CIN) was demonstrated following the introduction of ZedScan into routine use.

There was also a marked increase (57.4%) in the number of cases of high grade disease detected in women referred with mild or borderline abnormalities.

Benefits in patient management were also evident with the rate of treatment at first visit (‘See and Treat’), increasing from 36-39% in previous years to 61% of all high grade referrals; high grade disease was confirmed in 97.7% of the cases.

The report concludes that adoption of ZedScan has created opportunities for more efficient use of resources by offering ”See and Treat” as well as providing the reassurance to release women without disease to routine surveillance and reducing the need for further follow up.

Sameer Kothari, Chief Executive of Zilico Ltd, said:

This real-clinic patient data for ZedScan continues to demonstrate that the system improves the ability to identify and detect high grade disease.

 

ZedScan offers clinical benefits by identifying at first visit, those patients who require treatment, which also translates in to better health economics for the Hospital Trust.

 

ZedScan has also recently been integrated in to routine clinical practice at Central Manchester University Hospital Trust and we are currently in discussions with a number of other Trusts around the UK. We are also supporting healthcare systems across the globe in adopting ZedScan in to their cervical cancer care pathways.”

Zilico were supported by GM AHSN at a crucial stage in the purchase of the ZedScan system. Advisors offered expert support and advice on the procurement process, and on how to proceed with the sale. In addition Zilico, a Sheffield-based company, was helped to open a satellite office in Manchester. Read more about our work with Zilico.